

INDEX

SR. NO.	TOPIC	PAGE NO.
1	INTRODUCTION	1
1.1	WHO Guidelines for Quality Assessment of Herbal Medicines	2
1.2	Analysis of Raw Materials from Plants	3
1.3	Quality Control of Herbal Drugs	3
1.4	Finger-printing of Herbal Drugs	6
1.5	Parameters for Quality Control of Herbal Drugs and Herbal products	6
1.6	Toxicity of Herbal Drugs	12
1.7	Screening of Herbal Drugs	13
1.8	Standardization of Herbal Formulations	14
1.9	Need for standardization	16
1.10	Problems in Standardization	16
1.11	Traditional Ayurvedic formulations and Modern dosage forms	17
1.12	Modern approach based on Design of Experiments (DoE)	18
1.13	Immunity	18
1.14	Commercial herbal formulations for Immunity	22
1.15	References	23
2	REVIEW OF LITERATURE	27
2.1	Selection of herbs for polyherbal formulation	27
2.2	<i>Glycyrrhiza glabra</i>	30
2.3	<i>Nelumbo nucifera</i>	50
2.4	<i>Prunella vulgaris</i>	58
2.5	<i>Zizyphus jujuba</i>	66
2.6	References	76
3	AIMS AND OBJECTIVES	93
4	QUALITY ASSESSMENT OF PLANT RAW MATERIALS	95
4.1	Materials and methods	95

4.1.1	Plant material	95
4.1.2	Preparation of powdered material	95
4.1.3	Standardization of the plant materials as per the WHO guidelines	95
4.1.3.1	Macroscopic evaluation	95
4.1.3.2	Microscopic evaluation	95
4.1.3.2.1	Study of Transverse section:	95
4.1.3.2.2	Study of Powder characteristics	96
4.1.3.3	Determination of ash	96
4.1.3.4	Determination of Extractable matter	96
4.1.3.5	Determination of water and volatile matter	97
4.1.3.6	Determination of pesticide residues	97
4.1.3.7	Determination of heavy metals	97
4.1.3.8	Determination of microorganisms	97
4.1.3.9	Fluorescence analysis	98
4.1.3.10	Qualitative Phytochemical Screening	98
4.1.3.11	Estimation of secondary metabolites	99
4.1.4	<i>In- vitro</i> antioxidant activity	101
4.1.4.1	DPPH Free radical scavenging activity	102
4.1.4.2	Antioxidant capacity by Phosphomolybdenum complex method	103
4.2	Results and Discussion	103
4.2.1	Plant material	103
4.2.2	Standardization of the plant materials as per the WHO guidelines	104
4.2.2.1	Macroscopic evaluation	104
4.2.2.2	Microscopical and Histological analysis	105
4.2.2.3	Determination of ash	107
4.2.2.4	Determination of Extractable matter	108
4.2.2.5	Determination of water and volatile matter	108
4.2.2.6	Determination of pesticides residue	109
4.2.2.7	Determination of Heavy metals	109
4.2.2.8	Determination of microbial contamination	110

4.2.2.9	Fluorescence analysis	110
4.2.2.10	Qualitative Phytochemical Screening	112
4.2.3	Estimation of secondary metabolites	115
4.2.3.1	Determination of total phenolic content	115
4.2.3.2	Determination of total flavonoid content	117
4.2.3.2.1	Aluminium Chloride Colorimetric Method	117
4.2.3.2.2	2, 4-Dinitrophenylhydrazine Colorimetric Method	117
4.2.4	Preliminary in- vitro antioxidant activity	119
4.2.4.1	DPPH Free radical scavenging activity	119
4.2.4.2	Antioxidant capacity by phosphomolybdenum complex	120
4.3	CONCLUSION	122
4.4	REFERENCES	123
5	DEVELOPMENT OF ANALYTICAL METHODS	124
5.1	Analytical method development and validation	124
5.1.1	Materials and methods	124
5.1.1.1	Instrumentation	124
5.1.2	HPLC method for simultaneous estimation of Glycyrrhizin and Betulinic acid in Herbal formulation (Method I)	126
5.1.3	HPLC method for simultaneous estimation of glycyrrhizin, quercetin, rosmarinic acid and betulinic acid (Method II)	129
5.1.4	HPTLC method for estimation of quercetin estimation in <i>N. nucifera</i> extract (Method III)	132
5.1.5	HPTLC method for simultaneous estimation of glycyrrhizin, quercetin, rosmarinic acid and betulinic acid (Method IV)	135
5.1.6	Spectrofluorometric method for estimation of quercetin in <i>Nelumbo nucifera</i> extract and in Herbal formulation (Method V)	137
5.1.7	Spectrofluorometric method for estimation of glycyrrhizin in <i>Glycyrrhiza glabra</i> extract and in polyherbal formulation (Method VI)	139
5.2	RESULTS AND DISCUSSIONS	141
5.2.1	Simultaneous estimation of Glycyrrhizin and Betulinic acid in polyherbal formulation (Method I)	141

5.2.2	HPLC method development for simultaneous estimation glycyrrhizin, quercetin, rosmarinic acid and betulinic acid (Method II)	150
5.2.3	HPTLC method development for quercetin estimation in <i>N. nucifera</i> extract (method III)	158
5.2.4	HPTLC method development for simultaneous estimation glycyrrhizin, quercetin, rosmarinic acid and betulinic acid (Method IV)	164
5.2.5	Spectrofluorometric method for estimation of quercetin in <i>Nelumbo nucifera</i> extract and in polyherbal formulation (Method V)	169
5.2.6	Spectrofluorimetric method for estimation of glycyrrhizin in <i>Glycyrrhiza glabra</i> extract and in developed polyherbal formulation (Method VI)	172
5.3	CONCLUSION	175
5.4	REFERENCES	177
6	QUALITY ASSESSMENT OF DEVELOPED POLYHERBAL FORMULATION	182
6.1	Development of polyherbal formulation	182
6.2	Materials and Methods	182
6.2.1	Optimization of formulations by <i>in-vitro</i> antioxidant activity using full factorial designs	182
6.2.1.1	2x4 full factorial design	183
6.2.1.2	2x3 full factorial design	183
6.2.2	Development of Dosage form	184
6.2.2.1	Selection of Excipients	184
6.2.2.2	Method for the preparation of tablets (Direct Compression method)	184
6.2.3	Physical Standardization of Formulation	185
6.2.3.1	Evaluation parameters for extracts	185
6.2.3.2	Evaluation of dosage form	186

6.2.4	Accelerated stability studies of developed formulations according to WHO guidelines	188
6.2.5	BIOLOGICAL EVALUATION OF FORMULATION	188
6.2.5.1	Acute toxicity study	188
6.2.5.2	<i>In-Vivo</i> Immunomodulatory Activity	189
6.2.5.2.1	Cyclophosphamide induced myelosuppression assay	190
6.2.5.2.2	Carbon clearance assay in mice	191
6.2.5.2.3	Delayed hypersensitivity response in rats	191
6.2.5.2.4	Humoral Antibody titre	191
6.2.5.3	IN-VITRO STUDIES	194
6.2.5.3.1	Chemicals	194
6.2.5.3.2	Isolation of PMN cells from healthy human blood	194
6.2.5.3.3	Cell culture	195
6.2.5.3.4	Analysis of cell viability (MTT assay)	195
6.2.5.3.5	<i>In-vitro</i> immunomodulatory activity	196
6.2.5.3.5.1	Preparation of neutrophils	196
6.2.5.3.5.2	Pretreatment of neutrophils (activation) with formulations	196
6.2.5.3.5.3	Nitroblue tetrazolium (NBT) test	196
6.2.5.3.5.4	Neutrophils candidacidal assay	196
6.3	Statistical Analysis of Data	197
6.4	RESULTS AND DISCUSSIONS	198
6.4.1	Optimization of formulations by <i>in-vitro</i> antioxidant activity using full factorial designs	198
6.4.1.1	2x4 full factorial design	198
6.4.1.2	2x3 full factorial design	202
6.4.2	Development of Dosage form	206
6.4.3	Physical Standardization of the developed polyherbal tablet formulation	207

6.4.4	Accelerated stability studies of developed formulations according to WHO guidelines	212
6.4.5	Biological evaluation of formulation	213
6.4.5.1	Acute oral toxicity study	213
6.4.5.2	<i>In-vivo</i> Immunomodulatory Activity	214
6.4.5.2.1	Cyclophosphamide induced myelosuppression assay	214
6.4.5.2.2	Carbon clearance assay in mice	215
6.4.5.2.3	Delayed hypersensitivity response in rats	215
6.4.5.2.4	Humoral Antibody titre	216
6.4.5.3	<i>In-vitro</i> studies	218
6.4.5.3.1	Analysis of cell viability (MTT assay)	218
6.4.5.3.2	Nitroblue tetrazolium (NBT) test	221
6.4.5.3.3	Neutrophils candidacidal assay	222
6.5	Comparisons of Developed Polyherbal Formulation with Reported/Marketed Polyherbal Formulations for Immunomodulatory activity	225
6.6	CONCLUSION	226
6.7	REFERENCES	231
7	SUMMARY AND CONCLUSION	234
